key: cord-0766333-vo6xe7o6
authors: Chang, David; Saleh, Moussa; Gabriels, James; Ismail, Haisam; Goldner, Bruce; Willner, Jonathan; Beldner, Stuart; Mitra, Raman; John, Roy; Epstein, Laurence M.
title: Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin
date: 2020-04-21
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.04.032
sha: a199fe80dc37a8a078b6a6e584257d98ad6065f5
doc_id: 766333
cord_uid: vo6xe7o6

nan

Coronavirus 2019 has led to a rapid increase in hospital admissions, placing stress on healthcare systems that have a finite number of hospital beds, healthcare providers (HCPs), and medical supplies. Preliminary data suggest that hydroxychloroquine (HCQ) and azithromycin (AZM) may improve the clinical course in patients with . (1, 2) However, HCQ±AZM may increase the risk for arrhythmias and sudden cardiac death due to QT prolongation. (3, 4) Given the widespread use of HCQ±AZM, it is challenging to monitor all of these inpatients on telemetry. Performing serial electrocardiograms (ECGs) for QTc monitoring increases HCP exposures and personal protective equipment (PPE) use.

We placed Mobile Cardiac Outpatient Telemetry (MCOT) (BioTelemetry, Malvern, PA, USA) on patients receiving HCQ±AZM for COVID-19 on non-telemetry floors. Following a baseline ECG, subsequent ECGs were cancelled. Telemetry technicians applied the MCOTs and linked them to the device phone. Patients had bidaily QTc measurements while receiving HCQ±AZM. An electrophysiologist received "urgent alerts" and bidaily reports from BioTelemetry. A QTc>500ms and any arrhythmias generated "urgent alerts." If a patient was discharged to complete HCQ±AZM as an outpatient or remained hospitalized after completing HCQ±AZM, the MCOT was removed, sterilized, and reused.

In one week, 117 consecutive COVID-19-positive patients on HCQ±AZM without telemetry monitors received an MCOT. The average age was 60.2±14.9 years (range 27-93 years); 40.5% were female, 52.1% had hypertension, 28.2% had diabetes, 0.9% had heart failure, and 5.1% had coronary artery disease. All patients were treated with HCQ 400mg bidaily for one day followed by 200mg bidaily for four days. Fifty-one (43.6%) patients also received ≥1 doses of intravenous azithromycin 500mg. Forty (34.2%) patients also received ≥1 other QT prolonging medications. Over the course of 295 total patient days, there were 28 urgent alerts for 18 (15.4%) patients. Atrial fibrillation (AF) with a rapid ventricular response was the most common (15, 53.6%). There were five (17.9%) alerts for QTc>500ms ( Table 1 ). An electrophysiologist was contacted for urgent events within 3-5 minutes. Of the 28 urgent alerts, 12 did not warrant intervention (e.g. first-degree atrioventricular block). This study demonstrates that when hospital admission rates exceed the capacity of telemetry beds, the MCOT may be used to monitor for arrhythmias and assess the QTc. In 2017, the MCOT, which consists of a sensor and monitor network that communicate via Bluetooth, was FDA-approved for QTc measurement, analysis, and reporting. Once gathered, the data is forwarded to the monitor for analysis. After each use, MCOT may be rapidly "redeployed" to another patient.

In our experience, twenty-eight "urgent alerts" were communicated in near real-time to an electrophysiologist, of which 16 alerts resulted in management changes. In addition to the "urgent alerts," the MCOT afforded electrophysiologists the ability to monitor for QTc changes.

While HCQ±AZM may put patients at higher risk for drug-induced arrhythmias, none of our patients had arrhythmias that led to medication discontinuation. The MCOT also allowed for better utilization of HCPs and resources. By eliminating the need for serial ECGs, we reduced both HCP exposures and PPE use. 4 The limitations of MCOT include that the device was never approved to measure QTc for patients with AF or atrial flutter, QRS >160ms, and T-wave <5% of the peak QRS amplitude.

The single-center, non-randomized study design, and a healthy population from a cardiac standpoint, are other limitations. The MCOT must be used with caution in patients with significant cardiac disease.

In conclusion, innovative management of COVID-19 patients treated with HCQ±AZM is needed given the limited healthcare resources. The MCOT may be utilized for arrhythmia and QTc monitoring while reducing both HCP exposures and PPE use. 

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Azithromycin and the risk of cardiovascular death

Values listed are numbers (percentages) or means±standard deviations